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Chemical reactions are traditionally carried out in bulk solution, but in nature confined spaces, like cell
organelles, are used to obtain control in time and space of conversion. One way of studying these
reactions in confinement is the development and use of small reaction vessels dispersed in solution, such
as vesicles and micelles. The utilization of protein cages as reaction vessels is a relatively new field and
very promising as these capsules are inherently monodisperse, in that way providing uniform reaction
conditions, and are readily accessible to both chemical and genetic modifications. In this review, we aim
to give an overview of the different kinds of nanoscale protein cages that have been employed as
confined reaction spaces.
Introduction
Reactions in confined space are currently gaining much interest,
because these are expected to lead to unique characteristics of the
products and also to have a drastic impact on reaction kinetics.1,2
By performing enzymatic reactions in a confined space, scientists
try to mimic the way in which enzymes react in nature.
Compartmentalization occurs inside cells to create small separate
locations with a specialized function, in which high
concentrations of specific enzymes can be realized, and to achieve
control over the order in which the enzymes react. Often the
product of one reaction functions as a catalyst or substrate for
the following one.3 This might significantly decrease formation of
side-products and increase reaction rates. The study of enzymes
in confined spaces is therefore of crucial importance to gain
insight into the complex processes of the cell, for the develop-
ment of improved catalytic systems, for the synthesis of new
products, etc. Many studies concerning the encapsulation of
enzymes by using various spherical particles, such as liposomes,
polymersomes, and other aggregates, have been reported.4–7
However, due to their polydisperse nature, reaction conditions
vary considerably from particle to particle. Protein cages are very
monodisperse, and can potentially be of great use for the study of
enzymatic reactions in confined space. The application of protein
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cages for enzymatic reactions is a relatively new field and only
recently a few examples have been reported.8–12 In this way, these
materials might even be considered as simple mimics of protein
based organelles found in bacteria.
Protein cages do not only have potential applications in the
study of enzymatic reactions. In the past 20 years, the field of
biomineralization has demonstrated that protein cages can also
be used for the formation of highly monodisperse nanoparticles.
In these processes the protein cage has different functions: it
provides a constrained environment providing the proper
conditions for the formation of highly monodisperse nano-
particles, it prevents aggregation of the formed nanoparticles,
and in many cases it induces the mineralization reaction. It does
so by providing the molecular interactions between the organic
and inorganic phases that are crucial for the biomineralization
process.13 An example is the well-defined interior cavity of
protein cages like ferritin, which is used as a nanoreactor for the
synthesis of inorganic nanoparticles.15 Also viral cages and even
bacterial multi-enzyme complexes have been used for this
purpose.13 These systems have a high charge density at certain
regions in their inner cavity, which can act as nucleation sites for
the mineralization. Using these strategies, monodisperse single
crystal nanoparticles can be grown inside capsids and cages. In
addition the protein shell itself can be modified to add extra
functionality to the nanoparticles.
Protein cages
In nature, several proteins exist that carry or store metal ions and
minerals. These proteins can often be used as hosts for bio-
mineralization reactions. A well known and intensively studied
example is the iron-storage protein ferritin, which is discussed
below. Other proteins that are also being used for these purposes
are bacterial DNA binding proteins from starved cells (Dps)
ferritin and the small heat shock protein (sHsp).
Ferritin
Ferritins are a class of non-haem iron storage proteins that are
produced by animals, plants, fungi, and bacteria.16 In nature,
iron is stored within the multi-subunit protein shell as a hydrous
ferric oxide nanoparticle.17 Ferritins can withstand high
temperatures (85 C) and high pH values (8.5–9.0) which make
them attractive for use in covalent and non-covalent synthesis.18
Iron-free ferritin (apoferritin or holo-ferritin) is a protein
complex of approximately 450 kDa.19 It consists of 24 poly-
peptide subunits which assemble into a hollow sphere with outer
and inner diameters of 12 nm and 8 nm, respectively (Fig. 1).20
Fig. 1 Schematic representation of horse spleen ferritin. (a) Complete
structure of the 24-meric protein assembly. (b) Outer and inner diameters
of the protein cage.14 Reproduced with permission from Wiley-VCH
Verlag GmbH & Co, see ref. 14.
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Small channels located at the subunit junctions are required for
the release of iron and transport of other metal ions and small
organic molecules.21 The protein shell of ferritin has several
functions: it acquires FeII, catalyses its oxidation and induces
mineralization within the cavity, which can store up to 4500 iron
atoms. This high storage capacity is achieved by sequestering the
iron as a compact mineral, which resembles the structure of the
mineral ferrihydrite FeO(OH). To perform these functions,
the protein shell contains two structurally similar, but mecha-
nistically different protein subunits, the heavy (H) and light (L)
chains. The H-type subunit catalyses the oxidation of FeII to
FeIII, while the L-type subunit promotes mineralization inside the
protein cage.
In 1991, Mann and co-workers pioneered the use of ferritin as
a nanosized bioreactor. Their main goal was to produce mono-
disperse metal particles from other metals than iron inside the
ferritin cavity.22 They applied horse spleen apoferritin (HSFn) to
produce iron sulfide particles, as well as manganese oxide and
uranyl oxohydroxide crystals.22–24 The iron sulfide particles were
formed by an in situ reaction of the native iron oxide cores. By
reacting the ferritins with H2S or Na2S in an aqueous buffer, the
ferrihydrite cores were transformed into iron sulfide nano-
particles. Soon thereafter, they also showed that manganese
oxide could be formed by redox-driven reactions in the apo-
ferritin cavity.23
Using similar biomineralization strategies, many different
inorganic nanoparticles have since then been synthesized inside
the core of apoferritin. These include cobalt oxide, cobalt oxo-
hydroxide, chromium hydroxide, nickel hydroxide, indium
oxide, cadmium sulfide, cadmium selenide, zinc selenide,
magnetite, cobalt/platinum alloys, platinum and other parti-
cles.14,25–30 Some of the recent publications on inorganic nano-
material synthesis inside the apoferritin cavity, beyond particle
formation, are described in more detail below.
Douglas and co-workers studied the use of the protein con-
strained iron oxide core of ferritin as a photoreduction catalyst.31
In this work, the authors showed that the native ferric oxy-
hydroxide ferrihydrite Fe(O)OH encapsulated within the protein
cage of ferritin could act as a semiconductor photocatalyst for
the reduction of the highly toxic CrVI to the more benign CrIII.
With this strategy at hand, the same group used the ferritin
system to catalyze the photoreduction of CuII to a colloidal
dispersion of Cu0 with a narrow size distribution.32 It was also
observed that a higher CuII/ferritin ratio led to larger Cu0 particle
sizes.
A few years later, the group of Watanabe used a similar
approach for the development of a size-selective hydrogenation
biocatalyst.14 They encapsulated a Pd nanocluster inside the
apoferritin cavity by in situ chemical reduction of encased PdII
ions using NaBH4 (Fig. 2). This hybrid metal catalyst was
subsequently used for the hydrogenation of a series of olefins.
Ferritin contains eight negatively charged pores which are
located at the junctions of three subunits. Substrate charge might
therefore influence the diffusion of substrate into the cavity. The
effect of substrate charge on catalytic hydrogenation efficiency of
the Pd–apoferritin hybrid was therefore evaluated. When anionic
or bulky substrates were used, only low turnover frequencies
were obtained, but when small, cationic substrates were utilized,
high turnover frequencies were observed. These results suggest
that the system discriminates based on the size and charge of the
substrates.
After having successfully incorporated Pd-complexes in the
apoferritin cavity, Watanabe and co-workers proceeded with the
encapsulation of RhII-complexes for the polymerization of phe-
nylacetylene inside the cavity (Fig. 3).33 Because of the con-
strained environment of the ferritin cage, polymers with
a narrower weight distribution were obtained than when phe-
nylacetylene was polymerized by the same Rh-catalyst in bulk.
The resulting polymers also have a restricted molecular weight
(13 kg mol1), and just a few polymer chains can be prepared
within one apoferritin cage. This suggests that the polymeriza-
tion is limited by the available space in the ferritin cavity.
Kramer et al. synthesized silver nanoparticles within the cavity
of ferritin by using a similar encapsulation approach combined
with genetical modification of the ferritin interior.35 The authors
modified the C-terminus of the L-chain of ferritin with a dodec-
apeptide, AG4, which was previously identified from a phage
display library to be able to reduce silver ions to metallic silver.
This method yielded spherical particles with an average diameter
of 7  1 nm.
Recently, Kasyutich et al. developed another strategy to
synthesize homogeneous silver nanoparticles using ferritin
protein cages.34 It was already suggested in the literature that two
parameters are important for obtaining an efficient metal-ion
incorporation and a narrow size distribution of the formed
nanoparticles inside the protein cage. These are the ratio of
external/internal charge distribution36,37 and the number of
available metal-binding/nucleation sites.38 On the basis of the
literature data the authors utilized ferritin from the hyper-
thermophilic archaeon Pyrococcus furiosus (PfFt), a protein with
a distinctive charge distribution and fewer iron nucleation sites
compared to other ferritins. By using the PfFt-cage, silver
nanoparticles of 2.1  0.4 nm were obtained (Fig. 4), with a high
stability in water and a high thermal stability (up to 90 C).
Other ferritins did not give these results.
Aime et al. entrapped up to 10 GdIII-chelates in the cavity of
apoferritin, which resulted in a complex that exhibited high
relaxivity of water protons with potential applications in
Fig. 2 Schematic representation of the preparation of Pd–apoferritin.14
Reproduced with permission from Wiley-VCH Verlag GmbH & Co, see
ref. 14.
Fig. 3 Schematic representation of a Rh-catalyzed polymerization
inside apoferritin.33 Reproduced with permission fromACS publications,
see ref. 33.
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magnetic resonance imaging (MRI).39 Though this work is very
promising, it does not describe chemical reactions within the
cavity of protein cages and is therefore not further discussed
here.
The group of Mann also created magnetic nanoparticles by
synthesizing ferromagnetic nanocrystals of magnetite (Fe3O4)
40,41
and magnetite/maghemite (Fe3O4/g-Fe2O3)
42 within the ferritin
cavity to yield a magnetic protein, called ‘magnetoferritin’.
Apoferritin, loaded with various amounts of ironII ions, was
oxidized by trimethylamino-N-oxide (Fig. 5). In this method, the
authors used the unusual stability of the apoferritin cage at high
temperature (60 C) and pH (8.5). This approach resulted in the
formation of crystalline inorganic particles with diameters of
approximately 6–7 nm. A few years later, Klem et al. reported the
preparation of metal oxide nanoparticles containing both Fe and
Co oxides.43 By controlling the addition of Co to the reaction
mixture, a two- to fourfold increase in the ferromagnetic block-
ing temperature (with respect to ‘Fe-pure’ magnetoferritin), was
observed.
Dps ferritin
Dps are a member of the ferritin superfamily. They prevent DNA
damage by condensing DNA, and by accumulating iron atoms
within their central cavity that might otherwise have produced
free hydroxyl radicals by reaction with hydrogen peroxide.44,45
Dps uses the hydrogen peroxide to oxidize iron, resulting in an
iron oxide core similar to that of ferritins.46 Dps is structurally
similar to ferritin. Its 12 Dps subunits have a similar structure as
the ferritin subunits and the overall architecture resembles that of
the ferritin cage.47,48 As ferritin contains twice as much subunits
as Dps, the Dps cage is smaller, i.e. it has an outer diameter of
8.5 nm and an inner diameter of 5 nm. Structural analysis indi-
cates that the 0.8 nm pores at the subunit interfaces should allow
molecular access to the interior cavity of the protein cage.49 Dps
can accumulate 500 iron atoms within its small cavity. It is
suggested from X-ray crystal structural data that six clusters on
the interior surface could act as analogues of the mineral
nucleation sites in ferritin.49
The Dps protein cage was also utilized as a size and shape
constrained nanoreactor, as previously described for ferritin.
Ferrimagnetic iron oxide,15 cobalt oxide,50 cadmium sulfide51 and
platinum nanoparticles52 were synthesized within this cage. It is
worth mentioning that for the first time, the formation of these
particles was monitored by Kang et al. 52,53 by mass spectro-
metry.
To enhance the formation of nanoparticles, Swift et al.
replaced the 120 surface accessible hydrophilic residues of Dps
with hydrophobic amino acids.54 Despite these mutations, the
Dps proteins were still able to self-assemble and mineralize iron.
Heat shock proteins
Heat shock proteins are produced in high levels in response to
cellular stress, and assist in the correct folding of proteins. The
sHsp cage from the hyperthermophilic archaeon Methanococcus
jannaschii consists of 24 subunits of 16.5 kDa which self-assemble
into a cage with octahedral symmetry.55 The major difference
between this cage structure and that of the ferritins is the large
pores (3 nm in diameter) in the sHsp cage.56 The cage is stable in
the pH range 5–11 and can withstand temperatures up to 70 C.
It has an exterior diameter of 12 nm.
Douglas and co-workers functionalized both the interior and
exterior surfaces of sHsp with organic and inorganic groups.57 By
genetic manipulation of the protein, thiol groups and endoge-
nous amine groups on both the exterior and interior surfaces
were used to attach different molecules for the templating size-
constrained synthesis of inorganic materials. Because of the large
pores present in the sHsp cage, the functional groups on the
interior can easily react with guest molecules. This property has
also been used to achieve the chemical attachment of doxoru-
bicin, a chemotherapeutic agent, in the cavity of sHsp.58
Like ferritin, sHsp was also used as a reaction vessel for
biomimetic mineralization reactions.57,59 Transition metals, iron
oxide and alloy nanoparticles were entrapped and synthesized
within the sHsp protein cage.
Recently, the group of Douglas reported the synthesis of
a cross-linked, branched polymer network inside the protein cage
of sHsp.60A genetic sHsp construct with cysteine residues located
on its interior surface was used to initiate polymer growth by
reaction of the cysteines with a bromo-alkyn. Click-chemistry
was then applied to synthesize polymers within this cage, by the
sequential coupling of multifunctional monomers. It was
observed that the stability of cages increased dramatically upon
Fig. 4 Silver ions (yellow) access the cavity of Pyrococcus furiosus and
bind to the binding/nucleation centers at the internal surface. Ag nano-
particles are shown in orange.34 Reproduced with permission from ACS
publications, see ref. 34.
Fig. 5 Schematic representation of the formation of magnetoferritin
from native ferritin. First, the native ferrihydrite cores from horse spleen
ferritin are removed by dialysis at pH 4.5. Then, apoferritin is recon-
stituted with a FeII-solution under slow oxidative conditions at 60 C and
pH 8.5.41 Reproduced with permission from AAAS, see ref. 41.
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encapsulation of the branched polymer. The cages were able to
withstand heat treatment that would otherwise completely
disrupt the native protein cage.
Another heat shock protein, Hsp60, which has a cage of 17 nm
in diameter, self-assembles into an octadecameric double ring
cage structure, which stacks into patterned arrays. The subunits
were genetically modified to display a histidine sequence on the
interior of the cage, creating a region with high affinity for metal
ions. The modified cage was used to template the synthesis of Ni–
Pd alloy nanoparticles.61
Barrel-shaped protein assemblies
Barrel-shaped protein assemblies, such as molecular chaper-
onins, have also been used to accommodate inorganic nano-
particles. For example, GroEL is a protein assembly of 14
identical subunits, which stack into rings, yielding a barrel-shape
structure of 800 kDa with a diameter of 4.5 nm.62 Its function is
to bind denatured proteins and assist in their folding which takes
place in its cavity. Aida and co-workers used GroEL for the
encapsulation and triggered release of nanoparticles.63 However,
as far as we know, no examples of synthesis inside the cavity of
chaperonins have been reported.
Viruses
In nature, viruses infect host cells in which they replicate and
then exit the cell. During these processes, viruses encounter
a broad range of chemical environments. To be able to survive
the harsh conditions outside cells but release their cargo when
inside, viruses have balanced assembly and disassembly charac-
teristics. All viruses package viral nucleic acid, but many can
assemble (naturally or manipulated) into viral capsids, devoid of
genetic material, allowing scientists to replace the virus’ natural
cargo with a non-viral cargo compound. This can be accom-
plished in two different ways: the cargo can be synthesized in
a preassembled capsid, or the protein cage can assemble around
an existing cargo. The first method, in which the capsid itself acts
as a nanoreactor, is used for the biomineralization of inorganic
materials inside the capsid. The latter process is being referred to
as encapsidation.65
In contrast to the previously discussed protein cages, viruses
exhibit a much larger variety in sizes and shapes (Fig. 6). When
we look at their morphology, a distinction can be made between
icosahedral capsids (quasi-spherical structures) and helical
capsids (rod-shaped structures). Icosahedral capsids range in size
from 18 to 500 nm in diameter, but filamentous or rod-shaped
viruses like TMV can form rods up to 2 mm in length.65
Virus particles generally consist of several hundred protein
molecules which can self-assemble to form highly symmetrical
structures that contain the viral nucleic acid. The subunits from
which the viral capsid is built up can be manipulated both
genetically and chemically, often without changing the overall
architecture of the virus particles that they form. Like protein
cages, the interior of viruses can often be modified via the pores in
the capsid. Some viruses can self-assemble in the absence of the
endogenous nucleic acids.13
The variety in shape and size, and the self-assembly charac-
teristics make viruses very suitable for the controlled synthesis of
inorganic materials or the encapsulation of other materials.
When we regard viral capsids as molecular containers, three
surfaces can be exploited: the interior, the exterior, and the
interface between the protein subunits (Fig. 7).66 In this overview,
we will focus on the modification of the inside of viral capsids.
Biomineralization in viruses
Self-assembled protein cage structures, such as ferritin, have been
used for the constrained mineralization of inorganic nano-
particles (see above).15,17 However, protein cages are limited to
a very small range of sizes and the corresponding shapes. On the
Fig. 6 Cryo-electron micrograph and image reconstructions of a variety
of viral capsids.64 (A) Paramecium bursaria Chlorella virus type I (PCB-
1), 170 nm diameter. (B) Murine polyomavirus (MPV), 51 nm diameter.
(C) Cowpea mosaic virus (CMV), 31 nm diameter. (D) Cowpea chlorotic
mottle virus (CCMV), 28 nm diameter. (E) Satellite tobacco mosaic virus
(STMV), 18 nm diameter. (F) Small section of rod-shaped TMV, 18 by
300 nm. (G) Sulfolobus turreted icosahedral virus (STIV) isolated from
Yellowstone National Park. Reproduced with permission from AAAS,
see ref. 64.
Fig. 7 Schematic representation of the three important interfaces
available for chemical and genetic manipulation in a virus particle.64
Herein, we will focus on manipulations of the interior cavity of viral
capsids. Reproduced with permission from AAAS, see ref. 64.
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contrary, viruses exist in a wide range of sizes, and, e.g., the
CCMV is even known to occur in many different architectural
shapes.67
Also, because of their specific assembly and disassembly
characteristics, viral capsids allow scientists to change their
interior.13 Therefore, the protein cages of viruses are very suitable
for constrained synthesis of inorganic materials.
Douglas and Young were the first to perform inorganic
mineralization reactions inside the CCMV capsid. It was already
known68 that at a pH higher than 6.5 the capsid has 60 pores with
a diameter of 2 nm and this process is reversed when the pH is
lowered to 5.0. This property of CCMV was used for the oligo-
merization of tungstate (WO2
4) and vanadate V10O28
6 inside
the capsid, which occurs when the pH is lowered. This approach
yielded particles with an average diameter of 15 nm.69
A few years later, Douglas and Young showed that the charge
on the protein cage interior of CCMV can be altered from
cationic to anionic.13 This was carried out by replacing nine basic
residues at the N-terminus of the CCMV coat protein by gluta-
mic acid residues, but the assembly properties and stability of the
formed particle remained similar to the wild-type capsids. The
particles that are formed in this manner have a negatively
charged interior, which favors interactions with positively
charged ferrous and ferric ions. This makes the viral cage suitable
for the hydrolysis of FeII to iron oxide, which leads to the size and
shape constrained formation of nearly monodisperse iron oxide
particles, with an average diameter of 24 nm.13
In a similar approach, the group of Douglas was able to use the
CCMV capsid for the biomineralization of TiO2 nanoparticles.
70
In this study, the authors made use of the wild-type capsid to
attract negatively charged TiIV salts, which were subsequently
converted to monodisperse TiO2 nanoparticles by changing the
pH of the solution.
De la Escosura et al. were able to synthesize Prussian blue
nanoparticles with an average diameter of 18  1.7 nm, within
the cavity of CCMV.71 Prussian blue nanoparticles were formed
by a photo-initiated reaction. Negatively charged [Fe(C2O4)3]
3
was accumulated in the capsid interior and produced FeII ions
after photoreduction, which further reacted with encapsulated
[FeCN6]
3 to form the Prussian blue clusters (Fig. 8). This is one
of the first examples of the synthesis of potentially magnetic
nanoparticles inside viral capsids.
Another viral capsid that is being used for the constrained
synthesis of magnetic nanoparticles is bacteriophage T7.72 The
interior of this virus can be very easily modified because the
capsid is formed first, after which the nucleic acids are condensed
within it. The empty capsid is therefore also stable without DNA.
The T7 phage has an outer diameter of 55 nm, and the interior
diameter is around 40 nm. The growth of cobalt particles inside
the T7 phage was achieved by incubating the empty capsids with
a CoII solution, after which the mixture was reduced by sodium
borohydride to yield cobalt nanoparticles. By using this
approach, uniform cobalt particles of 42  2 nm were obtained.
Bacteriophage MS2 is an icosahedral capsid consisting of 180
identical subunits, which self-assemble to form particles with
a diameter of 27 nm. An important characteristic of this viral
capsid is that it has 32 pores of about 1.8 nm, which enable the
diffusion of small molecules into and out of the capsid interior.
The group of Francis altered the interior of the MS2 capsid by
functionalizing the tyrosine residues using diazo-transfer and
hetero-Diels–Alder reactions.73 This modification was used to
confine Gd3+ binding ligands in the capsids, which could be used
for MRI contrast imaging.74 Such chemical alterations of the
interior of the capsid may also facilitate chemical or enzymatic
reactions in the confined space of the nanoreactor, however, such
reactions have not been carried out yet.
TMV is a helical, rod-shaped virus of which the interior has
been used for the synthesis of nanowires, due to its anisotropic
shape and stability. TMV is stable in a wide range of conditions;
it can withstand pH ranges from 3.5 to 9.0, temperatures up to
90 C and organic solvents.66 The TMV capsid is made up of
2130 identical subunits, which are recruited by the RNA and
assemble around it into a 300  18 nm helical structure, with
a core of 4 nm in diameter (Fig. 9). The structure of TMV can be
seen as a series of rings (comprising 14 subunits) stacked on top
of each other. This results in an overall chiral structure and
inherent asymmetry which does not exist for icosahedral viruses.
This property allows for chemical and physical differentiation on
one end of the helical rod. TMV can easily be assembled in vitro
and the TMV aspect ratio is determined by pH, ionic strength
and protein concentration.18 TMV can also be produced in very
high quantities (kilogram scale) from the infected plant material
and because of its high stability, it can serve as a template in
a wide range of conditions.
Fig. 8 Schematic representation of the synthesis of Prussian blue
nanoparticles within the cavity of CCMV.71
Fig. 9 Cryo-electron imaging reconstructions of tobacco mosaic virus
(TMV). The virus is 300 nm in length, has a diameter of 18 nm and a 4 nm
channel.18 Reproduced with permission from Wiley-VCH Verlag GmbH
& Co, see ref. 18.
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The channel of TMV was first used for the synthesis of Ni and
Co nanowires with lengths up to micrometre range,75,76 sug-
gesting end-to-end assembly of individual capsids. Later, the
narrow channel was used to grow copper nanowires of 150 nm in
length and 3 nm diameter77 and bimetallic alloys of CoPt, CoPt3
and FePt3 up to 100 nm length and 4 nm diameter.
78
Furthermore, formation of small silver nanoparticles by
photochemical reduction of AgI salts at pH 7 within the channel
of TMV has also been reported.80 In the same publication
the authors describe the use of the exterior surface of TMV for
the controlled formation of gold and platinum nanoparticles.
The group of Francis reported a method for site-selective
modification of both the interior and exterior surfaces of TMV to
expand the range of applications for which the capsid can be
used.81
The exterior surface of TMV has been widely used as
a template for the synthesis of nanoparticles and nanotubes.76,80
These nanotubes are grown from deposited clusters of palladium,
platinum, and gold on the exterior TMV surface.
The M13 bacteriophage is another helical virus, which has
been extensively studied and has proven to be a valuable tool for
the development of functional nano-materials. The M13 bacte-
riophage does not have an inner cavity in which reactions can be
performed, but although this literature overview focuses on
reactions on the interior of protein cages, successful studies
towards applications validate the discussion of these materials.
The M13 bacteriophage consists of 2700 copies of the p8 coat
protein that assemble around circular single stranded DNA, and
minor coat proteins which cap the ends of the structure. The coat
proteins can be genetically modified to display peptides with
metal-binding sequences. By modification of the minor coat
proteins situated at the virus ends with ZnS binding sequences,
and incubation with a ZnS liquid crystalline suspension, the
viruses form highly ordered composite materials.82 A similar
strategy was used to position the virus on single-walled carbon
nanotubes (SWNTs). Besides modification of the minor coat
proteins with SWNT binding peptides, the major coat proteins of
this virus were modified with peptides capable of nucleating
amorphous iron phosphate (a-FePO4). A cross-linked network
of a-FePO4 coated viruses attached to SWNTs was thus created
(Fig. 10). This network is highly conductive, and was used as the
positive electrode of a lithium-ion battery.79 This battery is very
light-weight and can be produced and disposed of in an envi-
ronmental friendly manner, in contrast to conventional Li-ion
batteries.
Enzymatic reactions inside viral capsids
In the past few years, there has been a growing interest in
mimicking cellular compartments. As mentioned in the Intro-
duction, viruses could serve as useful model systems for the study
of enzymatic reactions in confined spaces, due to their mono-
dispersity and small internal volume. In addition, many viruses
contain pores through which substrates can enter the capsid. In
order to construct a viral nanoreactor, their assembly and
disassembly properties could be of use, as well as the accessibility
of the capsid to genetic and chemical modification. Despite these
promising applications, however, only very few of these viral
nanoreactors have been produced thus far.8,12,83,84
A virus that is particularly suitable for the construction of
a viral nanoreactor is CCMV. Under influence of the pH the
CCMV capsid devoid of nucleic acids can disassemble into
dimers, and reassemble again. This property can be used to
entrap enzymes within the capsid, by mixing the enzymes with
the disassembled capsid proteins at pH 7.5, and subsequently
lowering the pH to 5.0 to induce capsid assembly (Fig. 11).
Comellas-Aragones et al. used this approach to incorporate
horseradish peroxidase (HRP) enzymes in the inner cavity of
CCMV.8 The goal of this project was to study the activity of one
single-enzyme present in the capsid. Therefore, the concentration
of the enzyme in buffer was lowered to make sure that only one
enzyme or no enzyme was encapsulated in the capsid. The
enzymatic activity of the encapsulated HRP was examined by
confocal fluorescence microscopy. The non-fluorescent dihy-
drorhodamine 6G was used as a substrate. Under the influence of
HRP this substrate is oxidized to rhodamine 6G which is highly
fluorescent and thus can easily be monitored. The experiment
showed that the capsid acts as a nanoreactor and is permeable for
both the substrate and product (Fig. 12).
A few years later, Minten et al.84 developed a method to
encapsulate multiple proteins in the CCMV capsid. The strategy
previously described by Comellas-Aragones et al.8 could not be
applied in this study, because the encapsulation efficiency in this
method was too low to encapsulate multiple enzymes. Therefore,
the authors designed an approach that utilized non-covalent
anchoring of the target protein to the capsid protein dimers,
which upon addition of non-functionalized capsid protein could
be assembled into capsids containing proteins. As non-covalent
Fig. 10 Schematic representation of the formation of a virus based
battery. (A) The minor coat proteins of the M13 bacteriophage are
modified with SWNT binding peptides, and the major coat proteins are
modified with peptides capable of nucleating a-FePO4. (B) Addition of
the a-FePO4 templated virus nanowires to SWNTs results in a highly
conductive network, which is used as the positive electrode of a lithium-
ion battery.79 Reproduced with permission from AAAS, see ref. 79.
Fig. 11 Schematic representation of enzyme encapsulation in the
CCMV capsid. After disassembling into dimers at pH 7.5, the guest
enzyme is added and upon decreasing the pH to 5.0 the capsid assembles
with the enzyme entrapped in its cavity.8
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anchor, a small heterodimeric coiled-coil protein was used. The
capsid protein was modified with the positively charged coiled-
coil, while EGFP as a model-system was modified with the
negatively charged coiled-coil. When these two complexes were
mixed together, the EGFP–capsid protein complex was formed
(Fig. 13). After addition of wild-type capsid protein to the
complex, capsid formation was induced by lowering of the pH.
By varying the ratio between the wild-type capsid protein, and
the capsid–EGFP protein complex, the amount of encapsulated
proteins could be controlled, and up to 15 EGFPmolecules could
thus be encapsulated.
Following up on this work, Minten et al.12 used this strategy to
encapsulate multiple functional enzymes, Pseudozyma (formerly
antarctica) lipase B (PalB) in the capsid. Comparison of the
catalytic activity of the capsids containing different amounts of
encapsulated PalB with non-encapsulated PalB, revealed that the
encapsulated PalB converted the substrate more efficiently
(Fig. 13). Furthermore, increasing amounts of PalB in the capsid
seemed to have a negative effect on the conversion rates. This can
be explained by considering that the local concentration of
enzyme inside the capsid is higher than the concentration of
substrate. Therefore, the conversion rate of substrate molecules
does not change when more enzymes are present in the capsid,
and thus the overall conversion rate per enzyme decreases.
These examples clearly show the potential of virus capsids as
a nanoreactor, and in the future these capsids might be used for
multiple applications, such as performing cascade reactions in
the confined space of a virus-based reactor.
Not only plant viruses, but also animal viruses, like the poly-
omavirus family have been engineered in order to obtain nano-
capsules. Simian virus 40 (SV40) and murine polyomavirus
(MPV) have been studied extensively for their potential use in
delivering biologically active materials.85 These are icosahedral,
non-enveloped DNA viruses, with an outer diameter of about
45 nm. Their capsid consists of 72 pentamers of the major coat
protein VP1 (Fig. 14).86,87 The minor coat proteins VP2 and VP3
are associated with the VP1 proteins and are located on the
capsid interior. Recombinant VP1 pentamers can self-assemble
into genome-free icosahedral virus-like particles (VLPs) both
in vitro and in vivo.88–90
Recently, many VLPs have been exploited as delivery vehi-
cles.85 For polyomaviruses this has been achieved by genetically
fusing heterologous proteins to VP1 proteins.91,92 However, the
particles formed in these studies were irregular and had showed
poor solubility when expressed in E. coli.
Inoue et al. reported a novel strategy for the encapsulation of
proteins and enzymes into SV40 VLPs.83 In this work, EGFP was
fused to the C-terminus of the VP2 and VP3 minor coat proteins,
using a flexible linker. When these constructs were co-expressed
with VP1, VLPs with EGFP inside were obtained. The resulting
capsids retained their ability to bind to, and enter cells, after
which the EGFP was delivered. Next, yeast cytosine deaminase
(yCD) was encapsulated via the same method. This enzyme
converts cytosine to uracil and is used as a prodrug-converting
enzyme in gene therapy. It was demonstrated that upon encap-
sulation the yCD enzymes retained most of their activity.
To the best of our knowledge, no enzymatic reactions inside
other capsids have been described so far.
Helical viruses have not been used for the encapsulation of
enzymes because their internal channel is too narrow for these
purposes.1 However, Candida antarctica lipase B (CalB), more
recently renamed Pseudozyma antarctica lipase B (PalB), has
been linked to the surface of potato virus X (PVX).93 This virus
Fig. 12 Single-enzyme study on HRP (E) encapsulated within CCMV.
The substrate (S) diffuses into the capsid and is converted into a fluo-
rescent product (P) which accumulates before it diffuses out of the
capsid.8
Fig. 13 (A) In this schematic representation it is shown how the EGFP–
capsid protein complex together with the wild-type capsid protein
assemble into a capsid with EGFP in its interior cavity.84 (B) The effect of
encapsulation on the activity of PalB enzymes.12
Fig. 14 Architecture of the SV40 capsid. Arrangement of the pentamers
on the T ¼ 7 icosahedral lattice.87 Reproduced with permission from
Elsevier Ltd, see ref. 87.
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particle has a flexible rod-shaped structure, which is 500 nm in
length and has a diameter of 13 nm. It is build up from 1270
identical coat proteins. The authors linked the lipase to the N-
terminus of the coat protein by constructing a PalB-coat protein
fusion protein. In this way the PalB was positioned at the exterior
of the virus particle (Fig. 15). The lipase remained catalytically
active, and this work suggests that in the future multiple types of
enzymes can be linked to the exterior of a viral capsid, in order to
catalyze multi-step enzymatic synthesis. These types of reactions
are not constrained by the dimensions of the virus, and will
therefore not be discussed further in this overview.
Molecular microcompartments and bacterial enzymes
A family of bacterial proteins that resemble virus capsids are the
encapsulins (in the literature also referred to as linocin-like
proteins), which form assemblies with a diameter of about 20 nm
and have icosahedral symmetry. Although the sequence simi-
larity between encapsulins and viral proteins is weak, the
proteins show great structural similarity to virus capsid proteins.
These nanocompartments package enzymes, and are thus
excellent examples of nanoreactors. The group of Ban studied
this protein family94 and found two different proteins that can be
packaged within the encapsulins; i.e. a peroxidase or a protein
that has the same fold as ferritin monomers and contains the
ferroxidase active site. Interestingly, the pores of encapsulin
resemble those of ferritin. The proteins are attached to the
encapsulin shell using a C-terminal extension that interacts with
a binding site of the encapsulin proteins.
Besides nanocompartments, many bacterial species produce
microcompartments to confine enzymes that have toxic or
volatile intermediates, or to increase the local enzyme concen-
tration. These microcompartments are solely composed of
proteins. The carboxysome for example is a bacterial micro-
compartment that packages the enzyme ribulose bis-phosphate
carboxylase oxygenase (RuBisCO) by forming polyhedral bodies
with a diameter of 80–140 nm.95–97 Other examples are the Eut
and Pdu organelles, which also are likely to package enzymes
from metabolic pathways.98,99 A eukaryotic microcompartment
built of protein subunits is the vault particle.100
In contrast to protein microcompartments, where structural
proteins form the walls of the compartment, multi-enzyme
complexes exist, in which the enzymes themselves form the walls
of the complex. Substrates can enter these complexes but they are
not permeable to other macromolecules. Examples are lumazine
synthase,101 fungal fatty acid synthase102 and the pyruvate
dehydrogenase complex.103
Bacterial microcompartments
For diverse bacteria it is known that they produce proteinaceous
intracellular compartments to entrap enzymes, to confine them
and as such increase their local concentration.94 However, the
mechanisms by which bacterial microcompartments like etha-
nolamine utilization (Eut) and propanediol utilization (Pdu)
encapsulate their enzymes are not very well understood.
The best studied bacterial microcompartment is the carboxy-
some, which confines CO2 in the vicinity of RuBisCO to enhance
autotrophic CO2 fixation.
11 Although this microcompartment
can be viewed as a potential nanoreactor for enzymatic reac-
tions, since in nature its function is already to encapsulate
enzymes, no such applications of the carboxysome have been
published yet.
Another bacterial microcompartment that gains interest is the
Pdu which is used for the B12-dependent degradation of 1,2-
propanediol (1,2-PD). The first two steps of 1,2-PD degradation
occur in the lumen of Pdu, the last two in the cytoplasm of the
cell.11 Pdu consists of 14 different polypeptides, including seven
different shell proteins and four enzymes.104 The encapsulated
enzymes include CoA-dependent propionaldehyde dehydroge-
nase (PduP), which converts 1,2-PD to propionyl-CoA via
a propionaldehyde intermediate. The function of Pdu is to
sequester propionaldehyde to protect cells from DNA damage
and cytotoxicity.
Fan et al. showed that short N-terminal peptides of Pdu and
other proteinaceous microcompartments (MCPs) play a major
role in the encapsulation of enzymes.11 In the same publication,
the authors show that fusion of the 18-amino acid N-terminal
sequence of PduP to green fluorescent protein (GFP), gluta-
thione S-transferase (GST) or a maltose-binding protein (MBP)
resulted in their encapsulation in Pdu. Though the exact binding
mechanism of the N-terminal sequences to the microcompart-
ments is not known, from these experiments it is clear that they
play an essential role for the binding of certain enzymes to the
interior of the microcompartments.
Since recombinant enzymes containing these N-terminal
extensions are readily made, this discovery offers great potential
for the utilization of microcompartments as nanoreactors. As
these compartmental structures have only recently been discov-
ered and studied, this has not been accomplished yet, at least to
the best of our knowledge.
Vault nanoparticle
Vaults are large ribonucleoprotein capsules with dimensions of
42  42  75 nm,105 a thin protein shell of 2 nm thick,
surrounding an inner cavity large enough to encapsulate
hundreds of proteins (Fig. 16).9 Vaults consist of four compo-
nents: 96 copies of the major vault protein (MVP), vault poly-
(ADP ribose) polymerase (VPARP), telomerase-associated
protein 1 (TEP1), and untranslated vault RNA. Recombinant
MVPs expressed in insect cells can self-assemble into a vault-like
particle, without the remaining components.
The group of Rome has studied the properties of the vault
capsules, mainly for their potential as a drug delivery
vehicle.106,107 Because vaults are abundant in most eukaryotes,
including humans, they are less expected to elicit an
Fig. 15 Schematic representation of the PVX virus particle (yellow) with
the PalB enzyme molecules (red) on its surface.93 Reproduced with
permission from Nature publishing group, see ref. 93.
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immunogenic response than virus capsids or bacterial micro-
compartments.
First, the authors demonstrated that luciferase could be
encapsulated in the cavity of the vault, by fusing the luciferase
encoding DNA to the vault interaction domain and inserting it
into the baculovirus expression vector.108 In a similar way,
a variant of GFP (green lantern) was also sequestered within the
vault cavity. Luciferase was still active after encapsulation but its
activity seemed to be affected by a diffusion barrier for charged
molecules.
A few years later the same group showed that a semiconductor
polymer could be encapsulated in recombinant vaults.109 This
study provided important insight into the encapsulation process
of nonbiological cargos which could be applied in the seques-
tration of drug molecules. Recently, gold nanoclusters and
histidine-tagged proteins have been targeted to the inner wall of
vault particles by using a carrier derived from a vault lumen-
associated protein.106
Lumazine synthase
Lumazine synthase is a hollow 1MDa bacterial enzyme complex,
consisting of 60 subunits. It is involved in the synthesis of
lumazine, which is a precursor to riboflavin. X-Ray structure
analysis showed that lumazine synthase is a hollow sphere with
T ¼ 1 icosahedral symmetry, with an outer and inner diameters
of 14.7 nm and 7.8 nm respectively.110 The inner wall of the
capsid is negatively charged, due to the presence of glutamic acid
residues. The interior of the lumazine synthase capsid can be
accessed via hydrophilic channels, which are lined with the glu-
tamic acid residues and located at the ten threefold axes.101
Channels consisting of symmetrically arranged a-helices are
present along the six five-fold pentamer axes110 (Fig. 17). The
pores formed by these channels at the interior surfaces are sur-
rounded by polar residues and probably play an important role
in substrate import and product export from the enzyme catalytic
sites located at the interior of the complex.111 The capsid is highly
stable at pH 7 in the presence of phosphate buffer or substrate
analogues. In the absence of ligands, the structure can dynami-
cally be rearranged to form larger particles, with an external
diameter of 30 nm.112
Shenton et al. investigated the potential of the lumazine syn-
thase capsid as a bio-nanoreactor for the mineralization of iron
oxide.113 In the environment which the authors used for this
reaction (pH 6.5 and absence of ligands) the capsids had an
internal diameter of 20 nm and an external diameter of 30 nm, as
confirmed by transmission electron microscopy (TEM). Miner-
alization of iron oxide was induced by adding aliquots of FeII to
the buffer solution. The formation of electron dense iron-con-
taining nanoparticles was confirmed by TEM images and cor-
responding energy dispersive X-ray analysis (EDX). The ratio of
FeII ions/subunits lumazine synthase was varied in the experi-
ments. More FeII ions per subunit resulted in more electron dense
and more crystalline iron-containing nanoparticles. The diam-
eter of these particles varied between 10 and 15 nm. TEM
measurements on the iron-containing capsids revealed that the
formed capsids were mostly 30 nm in diameter, but that a small
percentage was in the native form of 15 nm in diameter. This
suggests that the native form is destabilized by the presence of
FeIII ions and transforms into a higher ordered structure. The
authors thus showed that it is possible to use a hollow bacterial
enzyme complex for the mineralization of inorganic nano-
particles. They also suggested that due to the presence of both
positively and negatively charged channels in the capsid, it
should be possible to sequester cationic and anionic reactions for
the synthesis of other nanoparticles (as previously demonstrated
for ferritin).
A few years later, Seebeck et al. reported an encapsulation
method for lumazine synthase which utilizes a tagging system
based on charge complementarity.10 The authors used lumazine
synthase from Aquifex aeolicus which they genetically engineered
in such a way that four residues per monomer, which project into
the lumen, were mutated to glutamic acid residues, to create an
additional negative charge on the interior surface of the capsid
(Fig. 18). As the capsids contain either 60 or 180 subunits, these
mutations, therefore, could yield 240 or 720 extra negative
charges, respectively. Furthermore, a histidine-tag was incorpo-
rated at the C-terminus of the protein to facilitate purification.
The negatively charged lumazine synthase was brought to
expression in E. coli and this yielded capsids which can withstand
temperatures up to 95 C. Next, the authors showed that
Fig. 16 Vault reconstruction with imposed eight-fold symmetry.9
Reproduced with permission from Elsevier Ltd, see ref. 9.
Fig. 17 Models of the 60-subunit lumazine synthase capsid. Left: view
from the 5-fold icosahedral axis; one of the 12 channels is clearly visible.
Right: view from the 3-fold icosahedral axis.110 Reproduced with
permission from Elsevier Ltd, see ref. 110.
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a positively charged stretch of amino acids added to a cargo
protein led to encapsulation of the cargo protein. This was
carried out by fusing a deca-arginine (R10) tag to the C-terminus
of GFP. When co-produced with the lumazine synthetase, GFP–
R10 was encapsulated in the negatively charged lumazine syn-
thase capsid. Sedimentation equilibrium data and scanning force
microscopy (SFM) revealed that both T¼ 1 capsids consisting of
60 subunits and T ¼ 3 capsids, consisting of 180 subunits were
formed.
Pyruvate dehydrogenase complex
Pyruvate dehydrogenase (PDH) multi-enzyme complexes of
icosahedral symmetry are found in the mitochondria of
eukaryotes and Gram-positive bacteria.114 These PDH-
complexes contain a dihydrolipoyl acetyltransferase (E2),
a pyruvate decarboxylase (E1), a dihydrolipoyl dehydrogenase
(E3), and, in the case of the mammalian enzymes, an E3-binding
protein and regulatory kinases and phosphatases. The E2
component of this complex consists of a 28 kDa catalytic
domain, a 4 kDa peripheral subunit-binding domain (PSBD) and
a 9 kDa lipoyl domain, which are connected by long stretches of
polypeptide chain thought to be largely flexible in conforma-
tion.115 In a native PDH-complex, 60 copies of E2 self-assemble
through interactions of their catalytic domains to form an
icosahedral structure, to which 42–48 copies of an a2b2-E1 (153
kDa) and 6–12 copies of a homodimeric E3 (100 kDa) bind
tightly around the outside (Fig. 19).114
The inner icosahedral shell formed by the E2 subunits is
approximately 24 nm in diameter and has 12 openings of 5 nm
each. Since this enzyme complex is derived from a thermophilic
organism, the association of the subunits into the multi-enzyme
complex has been shown to be stable at high temperatures.116
Domingo et al. showed that it is possible to display antibody
epitopes and EGFP on the outer surface of E2.117,118 This was
achieved by replacing the PSDB and lipoyl domains linked to the
E2 catalytic domain with either antibody epitopes or EGFP. The
resulting fusion protein was able to assemble, thus displaying
the epitopes and EGFP on the exterior of the complex. A few
years later, Dalmau et al. investigated the potential of the E2
scaffold as a potential molecular carrier.119 In this work, the
authors first synthesized a truncated gene encoding for E2 which
was optimized for expression in E. coli. By mutation of the E2
encoding gene, selected amino acids were changed to amino acids
with different physicochemical properties. Even after 120
mutations, the E2 complex still assembled into a dodecahedral
structure with high thermal stability. The cysteine mutants of the
scaffold were used to couple two fluorescent dyes, leading to its
sequestration into the inner cavity of the E2-complex. TEM
images showed that even after covalent encapsulation of the
molecules in the inner cavity, the dodecahedral structure
remained intact.
In this work, the authors describe a clear method to encap-
sulate foreign cargos in the cavity of the E2-complex. Their work
can be regarded as a tool for the encapsulation of enzymes in the
future.
Concluding remarks
In this review different examples of protein-based nanoreactors
have been described. These self-assembled structures all exist in
nature and can be chemically or genetically modified for the
creation of nanoparticles, or nanocatalysts.
Protein cages from ferritin and ferritin-like proteins were the
first bio-nanoreactors used for biomineralization reactions in
a constrained environment. A very wide range of inorganic
materials has been successfully synthesized within these cage-
structures. A few years later, the use of viral cages for the same
purposes became of great interest. Viral cages offer a similar
constrained reaction environment but exist in a wider range of
shapes and structures, for example the rod-shaped TMV and the
icosahedral CCMV, which enables the formation of nano-
particles of more diverse sizes and shapes. Also, some of the
viruses are known to be able to change their morphology upon
exposure to a changing environment, which increases the possi-
bilities even further. CCMV and TMV are now commonly used
to nucleate minerals in their cavities, but this field is still young
and it is very probable that in the future more applications for
viral capsids will be developed, like MRI contrast imaging
agents.
As mentioned before, one of the main advantages of using
protein cages for the synthesis of nanoparticles is the mono-
dispersity of the resulting particles. This is a direct result of the
monodispersity of the protein cages themselves, as the nano-
particles grow until they fill the interior of the capsid. It would be
expected therefore, that all nanoparticles formed in one type of
protein cage would be of the same size. This is, however, not
Fig. 18 Left: sequestration of GFP in the lumazine synthase capsid,
based on the crystal structure of the T ¼ 1 capsid formed by A. aeolicus.
Right: lumazine synthase pentamer. In red are the four mutated glutamic
acid residues.10 Reproduced with permission from ACS publications, see
ref. 10.
Fig. 19 Schematic representations of the PDH-complex. (A) Surface
representation of a three-dimensional model of an E2E3 complex, viewed
along the 3-fold axis of symmetry. (B) Same representation with a portion
of the outer protein shell removed to visualize the inner E2-core.114
Reproduced with permission from ASBMB, see ref. 114.
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always the case, as is shown by the different sizes of the nano-
particles formed within the CCMV capsid. Although all nano-
particles of the same type are very monodisperse, there is
a considerable size difference between different types of nano-
particles formed within the CCMV capsid, ranging from vana-
date particles of 15 nm in diameter,69 to iron particles of 24 nm in
diameter.13 This can be due to the presence of a ‘void space’
between the capsid shell and the nanoparticle. It is probable that
the size of this space is influenced by the encapsulated material
and possibly by the reaction conditions.
The confined space of protein cages has thus far mainly been
used for biomineralization reactions. The metal nucleation sites
have also been used to immobilize small inorganic catalysts on
the interior, which resulted in a nanoreactor that could initiate
polymerization of monomers inside the cage.33 The application
of protein cages for the immobilization of enzymes and the study
of enzymatic reactions has great potential, especially since the
discovery of bacterial microcompartments shows that nature
also uses protein cages for the encapsulation of enzymes to create
mini-organelles. Thus far only a few groups have published
methods to encapsulate proteins in protein cages10–12,83,108 and
even fewer have reported on enzymatic reactions inside the
cages,8,120 but the future for this field is very promising. A large
part of the research described in this review is therefore devoted
to this subject.
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